Skip to main content

Advertisement

Table 1 Characteristics of the 25 patients at baseline and at follow up (8 weeks of treatment)

From: Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study

Variables Visit 1 (Pre-treatment) Visit 2 (Post treatment) p
Age (years) 59.2 [55.2; 63.2] -  
Male gender (%) 13.0 (52.0%) -  
Current smoker 4.0 (16.0%) -  
Hypertension 19.0 (76.0%) -  
Cardiovascular disease 5.0 (20.0%) -  
Ischemic heart disease 4.0 (16.0%) -  
Ischemic stroke 1.0 (4%) -  
Medication    
ACEI 10.0 (40.0%) -  
β-Adrenergic receptor blocker 8.0 (32.0%) -  
Diuretics 8.0 (32.0%) -  
Calcium channel blocker 7.0 (28.0%) -  
Angiotensin receptor blocker 4.0 (16.0%) -  
Aspirin 7.0 (28.0%) -  
SBP (mmHg) 149.8 [143.5; 156.1] 142.7 [137.6; 147.8] 0.04
DBP (mmHg) 91.5 [87.4; 95.5] 87.5 [82.8; 92.2] 0.02
BMI (kg/m2) 28.7 [26.6; 34.2]a 28.7 [26.7; 34.0]a 0.79
Waist (cm) 108.5 [104.0; 113.0] 110.4 [105.5; 115.3] 0.06
FPG (mg/dl) 136.9 [129.0; 144.8] 137.6 [129.7; 145.5] 0.82
HbA1c (%) 6.5 [6.3; 6.8] 6.5 [6.3; 6.7] 0.53
Lipids    
Total cholesterol (mg/dl) 182.0 [166.0; 220.0]a 168.0 [151.0; 192.5]a 0.01
HDL cholesterol (mg/dl) 45.0 [40.1; 50.0] 44.1 [37.7; 50.5] 0.88
LDL-cholesterol (mg/dl) 104.0 [93.0; 139.3]a 102.0 [89.1; 125.6]a 0.14
Triglycerides (mg/dl) 168.6 [140.2; 197.0] 114.1 [95.4; 132.8] <0.001
eGFR (ml/min/1.73 m2) 107.7 [93.4; 122.0] 96.8 [82.6; 111.1] 0.007
TGO (IU/L) 20.0 [15.5; 25.0]a 22.0 [18.0; 26.0]a 0.10
TGP (IU/L) 22.0 [17.0; 27.0]a 24.0 [20.0; 28.0]a 0.48
  1. Data in table are presented as mean [95%CI] for continuous variables, median [1st quartile; 3rd quartile] for variables with abnormal distribution and number (%) for categorical variables; a- abnormal distribution; BMI - body mass index; HbA1c – glycosilated hemoglobin; SBP –systolic blood pressure; DBP – diastolic blood pressure; FPG – fasting plasma glucose; eGFR- estimated glomerular filtration rate.